

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 - 2028

<https://marketpublishers.com/r/A71AC181D58EN.html>

Date: February 2021

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: A71AC181D58EN

Abstracts

This report can be delivered to the clients within 72 Business Hours

Antibiotics Market Growth & Trends

The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.5% from 2021 to 2028. High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market. Moreover, rising awareness among patients and healthcare professionals and increasing involvement of regulatory bodies in the R&D activities of new therapies to treat infectious diseases are expected to propel the market growth over the forecast period.

An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline. For instance, in December 2018, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.

Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period. In February 2020, Merck received acceptance for a review of supplemental New Drug Application (sNDA) from the U.S. FDA for

RECARBRIO (imipenem, cilastatin, and relebactam) intended for HABP/VABP. This submission is anticipated to reinforce the continued dedication of the company to R&D pertaining to antibiotic therapies that address unmet medical needs.

Government reforms such as the Generating Antibiotics Incentives Now Act in the U.S. are projected to propel market growth in the coming years. This is further expected to facilitate the development process of advanced drugs. According to the Pew Charitable Trusts, about 30% of the outpatient oral antibiotic drug prescriptions are unnecessary and most of these prescriptions are for disease conditions against which antibiotics are not significantly effective, such as non-bacterial infections and acute respiratory conditions.

The market is highly competitive and major market players have almost similar market share. Pharmaceutical players are adopting strategies, including mergers & acquisitions, collaborations, and strategic alliances, to gain a competitive advantage. The major pharmaceutical companies are collaborating for developing novel therapies to reduce the cost burden of the drug development process. In December 2019, Appili Therapeutics signed an agreement with Saptalis Pharmaceuticals for the reformulation of antibiotic metronidazole. According to the agreement, Saptalis will be responsible for manufacturing, marketing of ATI-1501 in the United States. Moreover, in October 2018, Paratek Pharmaceuticals, Inc. entered into a license agreement for the development and commercialization of Seysara (sarecyline) with Allergan.

A group of key pharmaceutical players has launched AMR Action Fund worth USD 1 billion in July 2020. This fund is expected to support the research of innovative and novel antibiotics and is formed in collaboration with the European Investment Bank, the Wellcome Trust, and the World Health Organization.

Due to the lack of commercial success for newly developed antimicrobial drugs, government and non-government bodies have adopted strategies to incentivize antibiotic drug R&D activities. For instance, the government in alliance with BARDA is supporting several companies to boost the R&D activities in new therapies for infectious diseases. BARDA has also been associated with pharmaceutical companies, such as GSK, Tetrphase, and Basilea Astra Zeneca. CARB-X is investing around USD 109 million to support the early-stage development of potential therapeutic candidates.

Antibiotics Market Report Highlights

By action mechanism, the cell wall synthesis inhibitors segment accounted for

the largest share of 52.1% in 2020 and is anticipated to maintain its lead over the forecast period

Based on drug class, the cephalosporin segment held the second-largest share in 2020. Pipeline candidates in cephalosporin drug class such as Fetroja (cefiderocol), cefilavancin, and ceftobiprole are anticipated to drive the segment in the forecast period

The others' drug class segment is expected to grow at the fastest rate during the forecast period. The segment consists of various existing classes of antibiotics as well as some newly developed drugs, such as tetracycline, carbapenem, imidazole, peptides, lincosamides, and monoclonal antibodies

Asia Pacific was the largest regional market in 2020 and is expected to witness the fastest growth in the coming years owing to the rising consumption of antibiotics and high disease prevalence

North America emerged as the second-largest regional market in 2020 owing to government initiatives for the development of new therapies and better reimbursement scenario

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation and Scope
 - 1.1.1 Action Mechanism
 - 1.1.2 Drug Class
 - 1.1.3 Regional Scope
 - 1.1.4 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
 - 1.3.1 Purchased Database:
 - 1.3.2 GVR's Internal Database
 - 1.3.3 Secondary Sources
 - 1.3.4 Primary Research
 - 1.3.5 Details of Primary Research
- 1.4 Information or Data Analysis
 - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity Flow Analysis
 - 1.6.1.1 Approach 1: commodity flow approach
- 1.7 List of Secondary Sources
- 1.8 List of Abbreviations
- 1.9 Objectives
 - 1.9.1 Objective
 - 1.9.2 Objective
 - 1.9.3 Objective
 - 1.9.4 Objective

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Summary

CHAPTER 3 ANTIBIOTICS MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market Dynamics
 - 3.1.1 Market Driver Analysis
 - 3.1.2 Development of Advanced Products

- 3.1.3 Increasing Prevalence of Infectious Diseases
- 3.1.4 Growing Collaborations for Development of Antibiotics
- 3.1.5 Market Restraint Analysis
- 3.1.6 High R&D Cost
- 3.1.7 Development of Resistance against Antibiotics
- 3.2 Penetration and Growth Prospect Mapping
- 3.3 Business Environment Analysis Tools
 - 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
 - 3.3.2 Porter's Five Forces Analysis
 - 3.3.3 Industry Analysis - Ansoff Matrix
- 3.4 Pricing Analysis

CHAPTER 4 REGULATORY & POLITICAL FORCES

- 4.1 North America
- 4.2 Europe
- 4.3 Asia Pacific

CHAPTER 5 ANTIBIOTICS MARKET - SEGMENT ANALYSIS, BY ACTION MECHANISM, 2017 - 2028 (USD MILLION)

- 5.1 Action Mechanism Market Share Analysis, 2020 & 2028 (USD Million)
- 5.2 Segment Dashboard
- 5.3 Market Size & Forecasts and Trend Analysis, 2017 - 2028 (USD Million)
 - 5.3.1 Cell Wall Synthesis Inhibitors
 - 5.3.1.1 Cell wall synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
 - 5.3.2 Protein Synthesis Inhibitors
 - 5.3.2.1 Protein synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
 - 5.3.3 DNA Synthesis Inhibitors
 - 5.3.3.1 DNA synthesis inhibitors estimates and forecast, 2017 - 2028 (USD Million)
 - 5.3.4 RNA Synthesis Inhibitors
 - 5.3.4.1 RNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
 - 5.3.5 Mycolic Acid Inhibitors
 - 5.3.5.1 Mycolic acid inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
 - 5.3.6 Others

5.3.6.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

CHAPTER 6 ANTIBIOTICS MARKET - SEGMENT ANALYSIS, BY DRUG CLASS, 2017 - 2028 (USD MILLION)

6.1 Drug Class Market Share Analysis, 2020 & 2028 (USD Million)

6.2 Segment Dashboard

6.3 Market Size & Forecasts and Trend Analysis, 2017 to 2028 (USD Million)

6.3.1 Cephalosporin

6.3.1.1 Cephalosporin market estimates and forecast, 2017 - 2028 (USD Million)

6.3.2 Penicillin

6.3.2.1 Penicillin market estimates and forecast, 2017 - 2028 (USD Million)

6.3.3 Fluoroquinolone

6.3.3.1 Fluoroquinolone market estimates and forecast, 2017 - 2028 (USD Million)

6.3.4 Macrolide

6.3.4.1 Macrolide market estimates and forecast, 2017 - 2028 (USD Million)

6.3.5 Carbapenem

6.3.5.1 Carbapenem market estimates and forecast, 2017 - 2028 (USD Million)

6.3.6 Aminoglycoside

6.3.6.1 Aminoglycoside market estimates and forecast, 2017 - 2028 (USD Million)

6.3.7 Sulfonamide

6.3.7.1 Sulfonamides market estimates and forecast, 2017 - 2028 (USD Million)

6.3.8 7-ACA

6.3.8.1 7-ACA market estimates and forecast, 2017 - 2028 (USD Million)

6.3.9 Others

6.3.9.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

CHAPTER 7 ANTIBIOTICS MARKET - SEGMENT ANALYSIS, BY REGION, 2017 - 2028 (USD MILLION)

7.1 Regional Market Share Analysis, 2020 & 2028 (USD Million)

7.2 Regional Market Dashboard

7.3 North America

7.3.1 North America market estimates and forecast, 2017 - 2028 (USD Million)

7.3.2 U.S.

7.3.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)

7.4 Canada

7.4.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)

7.5 Europe

- 7.5.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.2 Germany
 - 7.5.2.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.3 U.K.
 - 7.5.3.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.4 Spain
 - 7.5.4.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.5 France
 - 7.5.5.1 France market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.6 Italy
 - 7.5.6.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
- 7.6 Asia Pacific
 - 7.6.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.6.2 Japan
 - 7.6.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.6.3 China
 - 7.6.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.6.4 India
 - 7.6.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.6.5 South Korea
 - 7.6.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.6.6 Thailand
 - 7.6.6.1 Thailand market estimates and forecast, 2017 - 2028 (USD Million)
- 7.7 Latin America
 - 7.7.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.7.2 Brazil
 - 7.7.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.7.3 Mexico
 - 7.7.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.7.4 Argentina
 - 7.7.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
- 7.8 Middle East & Africa
 - 7.8.1 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.8.2 South Africa
 - 7.8.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.8.3 UAE
 - 7.8.3.1 UAE market estimates and forecast, 2017 - 2028 (USD Million)
 - 7.8.4 Saudi Arabia
 - 7.8.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE

8.1 Participant Categorization

8.1.1 Innovators

8.1.2 Market Leaders

8.2 Strategy Mapping

8.2.1 Key Strategies Chosen by Players in this Market Include:

8.2.1.1 Launch of new products

8.2.1.2 Acquisition

8.2.1.3 Expansion

8.2.1.4 Agreements, collaborations, partnerships

8.2.1.5 Others (realignment, divestment, market penetration):

8.3 Strategic Framework

8.3.1 Key Company Market Share Analysis, 2020

8.4 Company Profiles

8.4.1 Allergan (AbbVie Inc.)

8.4.1.1 Company overview

8.4.1.2 Financial performance

8.4.1.3 Product benchmarking

8.4.1.4 Strategic initiatives

8.4.2 Merck & Co., Inc

8.4.2.1 Company overview

8.4.2.2 Financial performance

8.4.2.3 Product benchmarking

8.4.2.4 Strategic initiatives

8.4.3 Cumberland Pharmaceuticals, Inc.

8.4.3.1 Company overview

8.4.3.2 Financial performance

8.4.3.3 Product benchmarking

8.4.3.4 Strategic initiatives

8.4.4 GlaxoSmithKline plc

8.4.4.1 Company overview

8.4.4.2 Financial performance

8.4.4.3 Product pipeline

8.4.4.4 Strategic initiatives

8.4.5 Novartis AG

8.4.5.1 Company overview

8.4.5.2 Financial performance

- 8.4.5.3 Product pipeline
- 8.4.5.4 Strategic initiatives
- 8.4.6 Melinta Therapeutics
 - 8.4.6.1 Company overview
 - 8.4.6.2 Product benchmarking
 - 8.4.6.3 Strategic initiatives
- 8.4.7 Teva Pharmaceutical Industries Ltd.
 - 8.4.7.1 Company overview
 - 8.4.7.2 Financial performance
 - 8.4.7.3 Product benchmarking
- 8.4.8 Nabriva Therapeutics plc
 - 8.4.8.1 Company overview
 - 8.4.8.2 Financial performance
 - 8.4.8.3 Product benchmarking
 - 8.4.8.4 Strategic initiatives
- 8.4.9 Mylan N.V.
 - 8.4.9.1 Company overview
 - 8.4.9.2 Financial performance
 - 8.4.9.3 Product benchmarking

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviations

Table 3 Approved Treatment for cIAI

Table 4 Approved Treatment for cUTI

Table 5 Approved Treatment for Gonorrhea

Table 6 Approved Treatment for ABSSSI

Table 7 Approved Treatment for CDI

Table 8 Approved Treatment for CAP

Table 9 Approved Treatment for HAP

Table 10 Examples of Cephalosporin

Table 11 Examples of Penicillin

Table 12 North America Antibiotics Market, By Country, 2017 - 2028 (USD Million)

Table 13 North America Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 14 North America Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 15 U.S. Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 16 U.S. Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 17 Canada Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 18 Canada Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 19 Europe Antibiotics Market, By Country, 2017 - 2028 (USD Million)

Table 20 Europe Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 21 Europe Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 22 U.K. Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 23 U.K. Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 24 Germany Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 25 Germany Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 26 France Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 27 France Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 28 Spain Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 29 Spain Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 30 Italy Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

Table 31 Italy Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

Table 32 Asia Pacific Antibiotics Market, By Country, 2017 - 2028 (USD Million)

Table 33 Asia Pacific Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)

- Table 34 Asia Pacific Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 35 Japan Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 36 Japan Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
- Table 37 China Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 38 China Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 39 India Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 40 India Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 41 South Korea Antibiotics Market, By Action Mechanism 2017 - 2028 (USD Million)
- Table 42 South Korea Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
- Table 43 Thailand Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 44 Thailand Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 45 Latin America Antibiotics Market, By Country, 2017 - 2028 (USD Million)
- Table 46 Latin America Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 47 Latin America Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 48 Brazil Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 49 Brazil Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
- Table 50 Mexico Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 51 Mexico Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 52 Argentina Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 53 Argentina Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 54 Middle East & Africa Antibiotics Market, By Country, 2017 - 2028 (USD Million)
- Table 55 Middle East & Africa Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 56 Middle East & Africa Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 57 South Africa Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 58 South Africa Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 59 Saudi Arabia Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 60 Saudi Arabia Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
- Table 61 UAE Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
- Table 62 UAE Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Antibiotics market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Antibiotics market snapshot
- Fig. 10 Antibiotics market driver impact
- Fig. 11 Antibiotics market restraint impact
- Fig. 12 Penetration and growth prospect mapping
- Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
- Fig. 14 Porter's five forces analysis
- Fig. 15 Ansoff matrix
- Fig. 16 Antibiotics market: action mechanism outlook and key takeaways
- Fig. 17 Antibiotics market: action mechanism movement analysis
- Fig. 18 Action mechanism segment dashboard
- Fig. 19 Cell wall synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 20 Protein synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 21 DNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 22 RNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 23 Mycolic acid inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 24 Others market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 25 Antibiotics market: Drug class outlook and key takeaways
- Fig. 26 Antibiotics market: Drug class movement analysis
- Fig. 27 Drug class segment dashboard
- Fig. 28 Cephalosporin market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 29 Penicillin market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 30 Fluoroquinolone market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 31 Macrolide market estimates and forecast, 2017 - 2028 (USD Million)

- Fig. 32 Carbapenem market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 33 Aminoglycoside market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 34 Sulfonamide market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 35 7-ACA market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 36 Others market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 37 Antibiotics market: Regional outlook and key takeaways
- Fig. 38 Regional outlook, 2020 & 2028 (USD Million)
- Fig. 39 Regional market dashboard
- Fig. 40 North America
- Fig. 41 North America market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 42 U.S.
- Fig. 43 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 44 Canada
- Fig. 45 Canada market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 46 Europe
- Fig. 47 Europe market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 48 Germany
- Fig. 49 Germany market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 50 U.K.
- Fig. 51 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 52 Spain
- Fig. 53 Spain market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 54 France
- Fig. 55 France market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 56 Italy
- Fig. 57 Italy market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 58 Asia Pacific
- Fig. 59 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 60 Japan
- Fig. 61 Japan market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 62 China
- Fig. 63 China market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 64 India
- Fig. 65 India market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 66 South Korea
- Fig. 67 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 68 Thailand
- Fig. 69 Thailand market estimates and forecast, 2017 - 2028 (USD Million)
- Fig. 70 Latin America

Fig. 71 Latin America market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 72 Brazil

Fig. 73 Brazil market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 74 Mexico

Fig. 75 Mexico market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 76 Argentina

Fig. 77 Argentina market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 78 Middle East & Africa

Fig. 79 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 80 South Africa

Fig. 81 South Africa market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 82 UAE

Fig. 83 UAE market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 84 Saudi Arabia

Fig. 85 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

Fig. 86 Participant categorization

Fig. 87 Strategy mapping

Fig. 88 Strategic framework

Fig. 89 Company market share analysis

I would like to order

Product name: Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 - 2028

Product link: <https://marketpublishers.com/r/A71AC181D58EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A71AC181D58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970